Sugi Predict

Sugi Predict / Compounds / SCHEMBL6493285

SCHEMBL6493285

SCHEMBL6493285

c1ccc2c(c1)Oc1cc(NCc3ccnc4ccccc34)ccc1S2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.38
▸ KDR P35968 5/20 0.38
▸ FLT1 P17948 4/20 0.38
▸ HTR1A P08908 2/20 0.37
▸ ADRA1D P25100 2/20 0.37
▸ ADRA1A P35348 2/20 0.37
▸ ADRA1B P35368 2/20 0.37
▸ RAF1 P04049 1/20 0.37
▸ LCK P06239 1/20 0.37
▸ RET P07949 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ KIT P10721 1/20 0.37
▸ MAP3K20 Q9NYL2 1/20 0.37
▸ RIPK3 Q9Y572 1/20 0.37
▸ BRD4 O60885 1/20 0.36
▸ PDE5A O76074 1/20 0.34
▸ FERMT2 Q96AC1 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888840 0.89 KDR (0.36) LOXL2KDRFLT1HTR1AADRA1D
SCHEMBL6530022 0.85 LOXL2 (0.44) LOXL2KDRFLT1HTR1AADRA1D
SCHEMBL7551761 0.83 MEN1 (0.40) KDRFLT1MAPT
SCHEMBL6495923 0.79 PTPN11 (0.52) CYP3A4GAAMAPTRAB9A
SCHEMBL6491307 0.77 PTPN1 (0.46) GAA
SCHEMBL6495422 0.76 UTS2R (0.40) CYP3A4GAAMAPTRAB9A
SCHEMBL6491982 0.76 MAPT (0.43) GAAMAPTRAB9A
SCHEMBL6491909 0.76 FFAR1 (0.44) CYP3A4GAAMAPTRAB9A
SCHEMBL6481801 0.75 MAOA (0.39) KDRCYP3A4BRD4MAPTRAB9A
SCHEMBL6482039 0.75 LOXL2 (0.42) LOXL2KDRFLT1HTR1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 — — US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 — — US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 — — EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 — — WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 — — US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 — — US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 — — US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 — — EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 LOXL2 2681/4885KDR 1823/4885FLT1 4107/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 LOXL2 4224/4885KDR 1651/4885FLT1 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.